CL2016001218A1 - Tienopirimidinas como inhibidores mknk1 y mknk2 - Google Patents

Tienopirimidinas como inhibidores mknk1 y mknk2

Info

Publication number
CL2016001218A1
CL2016001218A1 CL2016001218A CL2016001218A CL2016001218A1 CL 2016001218 A1 CL2016001218 A1 CL 2016001218A1 CL 2016001218 A CL2016001218 A CL 2016001218A CL 2016001218 A CL2016001218 A CL 2016001218A CL 2016001218 A1 CL2016001218 A1 CL 2016001218A1
Authority
CL
Chile
Prior art keywords
mknk1
mknk2
inhibitors
thienopyrimidines
compounds
Prior art date
Application number
CL2016001218A
Other languages
English (en)
Inventor
Philip Lienau
Lars Wortmann
Georg Kettschau
Keith Graham
Anja Richter
Florian Puehler
Franziska Siegel
Detlev Sülzle
Ulrich Klar
Kirstin Petersen
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CL2016001218A1 publication Critical patent/CL2016001218A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPUESTOS DERIVADOS DE TETRAHIDRO[1]BENZOTIENO[2, 3-D]PIRIMIDINA SUSTITUIDOS, INHIBIDORES MKNK1 Y MKNK2; METODO PARA PREPARARLOS; COMPOSICION FARMACEUTICA; COMBINACION FARMACEUTICA; COMPUESTOS INTERMEDIARIOS; Y SU USO PARA PREVENIR O TRATAR UN TRASTORNO HIPERPROLIFERATIVO Y/O DE ANGIOGENESIS TAL COMO UN TUMOR O UNA METASTASIS.
CL2016001218A 2013-11-20 2016-05-20 Tienopirimidinas como inhibidores mknk1 y mknk2 CL2016001218A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13193665 2013-11-20
EP14174731 2014-06-27

Publications (1)

Publication Number Publication Date
CL2016001218A1 true CL2016001218A1 (es) 2016-12-16

Family

ID=52000798

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016001218A CL2016001218A1 (es) 2013-11-20 2016-05-20 Tienopirimidinas como inhibidores mknk1 y mknk2

Country Status (22)

Country Link
US (1) US20160297833A1 (es)
EP (1) EP3071577A1 (es)
JP (1) JP2016539113A (es)
KR (1) KR20160086404A (es)
CN (1) CN106061980A (es)
AP (1) AP2016009225A0 (es)
AU (1) AU2014352066A1 (es)
BR (1) BR112016011472A2 (es)
CA (1) CA2930873A1 (es)
CL (1) CL2016001218A1 (es)
CR (1) CR20160235A (es)
CU (1) CU20160072A7 (es)
DO (1) DOP2016000118A (es)
EA (1) EA201600398A1 (es)
IL (1) IL245404A0 (es)
MX (1) MX2016006631A (es)
PE (1) PE20160593A1 (es)
PH (1) PH12016500931A1 (es)
TN (1) TN2016000194A1 (es)
TW (1) TW201605867A (es)
UY (1) UY35848A (es)
WO (1) WO2015074986A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
SG11201803234TA (en) 2015-10-29 2018-05-30 Effector Therapeutics Inc Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
US10112955B2 (en) * 2015-10-29 2018-10-30 Effector Therapeutics, Inc. Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2
US10000487B2 (en) 2015-11-20 2018-06-19 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
CA3050599A1 (en) 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
WO2018152117A1 (en) 2017-02-14 2018-08-23 Effector Therapeutics, Inc. Piperidine-substituted mnk inhibitors and methods related thereto
AU2019366947A1 (en) 2018-10-24 2021-06-03 Effector Therapeutics, Inc. Crystalline forms of Mnk inhibitors
CN110981903A (zh) * 2019-11-28 2020-04-10 南京正济医药研究有限公司 一种艾日布林中间体化合物提高光学纯度的精制方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100343258C (zh) * 2001-04-30 2007-10-17 美国拜尔公司 新的4－氨基－5,6－取代的噻吩并[2,3－d]嘧啶化合物
WO2003059913A1 (en) * 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
ES2280040T3 (es) * 2003-07-24 2007-09-01 Bayer Pharmaceuticals Corporation Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos.
CA2577664A1 (en) * 2004-08-20 2006-03-02 Bayer Pharmaceuticals Corporation Novel heterocycles
AR052019A1 (es) * 2004-10-15 2007-02-28 Bayer Pharmaceuticals Corp COMPUESTOS HETEROCICLICOS, PROCESOS DE PREPARACIoN Y MÉTODO PARA TRATAR ENFERMEDADES HIPERPROLIFERATIVAS
WO2006136402A1 (en) * 2005-06-22 2006-12-28 Develogen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
WO2007059905A2 (en) * 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
ES2547905T3 (es) * 2010-02-26 2015-10-09 Evotec International Gmbh 4-[Cicloalquiloxi(hetero)arilamino]-tieno[2,3-d]pirimidinas que tienen actividad inhibidora de la Mnk1/Mnk2 para composiciones farmacéuticas
TW201728592A (zh) * 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Ｉｒａｋ抑制劑及其用途
WO2013174735A1 (en) * 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
EP2852596B1 (en) * 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Thienopyrimidines
JP2015518842A (ja) * 2012-05-21 2015-07-06 バイエル ファーマ アクチエンゲゼルシャフト 置換ピロロピリミジン
EP2951187A1 (en) * 2013-02-01 2015-12-09 Bayer Pharma Aktiengesellschaft Substituted thienopyrimidines and pharmaceutical use thereof
AU2014289415A1 (en) * 2013-07-08 2016-01-21 Bayer Pharma Aktiengesellschaft Substituted pyrazolo-pyridinamines

Also Published As

Publication number Publication date
US20160297833A1 (en) 2016-10-13
AP2016009225A0 (en) 2016-05-31
EP3071577A1 (en) 2016-09-28
CA2930873A1 (en) 2015-05-28
JP2016539113A (ja) 2016-12-15
AU2014352066A1 (en) 2016-05-26
PH12016500931A1 (en) 2016-06-27
EA201600398A1 (ru) 2016-10-31
KR20160086404A (ko) 2016-07-19
MX2016006631A (es) 2016-08-17
CU20160072A7 (es) 2016-10-28
DOP2016000118A (es) 2016-06-30
UY35848A (es) 2015-06-30
WO2015074986A1 (en) 2015-05-28
TN2016000194A1 (en) 2017-10-06
PE20160593A1 (es) 2016-07-13
IL245404A0 (en) 2016-06-30
CN106061980A (zh) 2016-10-26
BR112016011472A2 (pt) 2017-09-26
CR20160235A (es) 2016-07-20
TW201605867A (zh) 2016-02-16

Similar Documents

Publication Publication Date Title
CL2016001218A1 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
IL269635B (en) History of conazole used to treat hiv
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
PH12016500676A1 (en) Pyrimidine fgfr4 inhibitors
MX362582B (es) Compuestos triciclicos fusionados de urea como inhibidores de raf quinasa y/o dimero de raf quinasa.
EP4324473A3 (en) Multiparametric nucleic acid optimization
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
WO2014194117A3 (en) Novel metalloproteases
DK2922828T3 (da) 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer
GB201520815D0 (en) Hydraulic fracturing composition, method for making and use of same
EP3082820A4 (en) Methods for modulating the amount of rna transcripts
EP3085380A4 (en) Composition for treating prostate cancer
BR112016017402A2 (pt) fusões anti-pcsk9~glp-1 e métodos para uso
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
BR112015008113A2 (pt) novo processo para preparar compostos para uso no tratamento de câncer.
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
CL2016000351A1 (es) Método para la cuantificación de actinio-227 en composiciones de radio-223.
EP3186270A4 (en) Cyclic urea compounds as granzyme b inhibitors
EA201691036A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201690914A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EP2968390A4 (en) INJECTABLE FORMULATIONS FOR THE TREATMENT OF CANCER
WO2014188201A3 (en) Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
CL2013000466S1 (es) Boquilla para implemento de maquina acondicionadora de terrenos
CL2013000468S1 (es) Boquilla para implemento de maquina acondicionadora de terrenos